Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis
Open Access
- 1 February 2006
- Vol. 61 (2) , 140-145
- https://doi.org/10.1136/thx.2005.042275
Abstract
Background: It is thought that overexpression of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) might compromise patient survival, presumably by promoting tumour growth by an autocrine mechanism. However, conflicting results have been reported from various laboratories, and the clinical importance of EGFR overexpression remains unsettled. Methods: A meta-analysis of previous studies was performed to quantitatively review the effects of EGFR overexpression on survival in patients with NSCLC using a DerSimonian-Laird random effects model. Eighteen studies including 2972 patients were subjected to final analysis. Results: Overall, positivity for EGFR overexpression differed between histological types: 39% in adenocarcinomas, 58% in squamous cell carcinomas, 38% in large cell carcinomas, and 32% in cancers in a miscellaneous category (pConclusions: EGFR overexpression was not associated with poorer survival in patients with NSCLC. Specific mutations of the EGFR gene will need further study in terms of survival implications.Keywords
This publication has 67 references indexed in Scilit:
- Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung CancerClinical Cancer Research, 2004
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancerBritish Journal of Cancer, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Elevated serum epidermal growth factor receptor level is correlated with lymph node metastasis in lung cancerInternational Journal of Clinical Oncology, 2003
- Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinomaSurgical Oncology, 1994
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985